0001193125-18-080861.txt : 20180313 0001193125-18-080861.hdr.sgml : 20180313 20180313172101 ACCESSION NUMBER: 0001193125-18-080861 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20180313 DATE AS OF CHANGE: 20180313 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AETNA INC /PA/ CENTRAL INDEX KEY: 0001122304 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 232229683 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16095 FILM NUMBER: 18687422 BUSINESS ADDRESS: STREET 1: 151 FARMINGTON AVENUE CITY: HARTFORD STATE: CT ZIP: 06156 BUSINESS PHONE: 8602730123 MAIL ADDRESS: STREET 1: 151 FARMINGTON AVENUE CITY: HARTFORD STATE: CT ZIP: 06156 FORMER COMPANY: FORMER CONFORMED NAME: AETNA U S HEALTHCARE INC DATE OF NAME CHANGE: 20000822 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 425 1 d507907d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2018

 

 

 

LOGO

CVS HEALTH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

(State or Other Jurisdiction

of Incorporation)

 

001-01011   05-0494040

(Commission

File Number)

 

(IRS Employer

Identification No.)

One CVS Drive  
Woonsocket, Rhode Island   02895
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

A special meeting of stockholders (the “Special Meeting”) of CVS Health Corporation (“CVS Health”) was held on March 13, 2018. A total of 795,074,680 shares of CVS Health common stock, out of a total of 1,015,460,751 shares of CVS Health common stock outstanding and entitled to vote as of the close of business on February 5, 2018 (the record date for the Special Meeting), were present in person or represented by proxy. A summary of the voting results for the following proposals, each of which is described in detail in the joint proxy statement/prospectus of CVS Health and Aetna Inc. (“Aetna”) dated February 9, 2018, which was first mailed to CVS Health’s stockholders on or about February 12, 2018, is set forth below:

Proposal 1. Approval of the Issuance of Shares of CVS Health Common Stock

CVS Health’s stockholders approved the issuance of shares of CVS Health common stock (the “Stock Issuance”) to shareholders of Aetna in the merger between Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of CVS Health Corporation, contemplated by the Agreement and Plan of Merger, dated as of December 3, 2017, as it may be amended from time to time, among CVS Health, Hudson Merger Sub Corp., and Aetna. The proposal was approved by the stockholders by the votes set forth in the table below:

 

  Votes For  

 

  Votes Against  

 

  Abstentions  

 

  Broker Non-Votes  

781,873,839   10,539,152  

2,661,689

  N/A

Proposal 2. Adjournment of the Special Meeting

Because there were sufficient votes at the time of the Special Meeting to approve the Stock Issuance, a vote was not called on the proposal to adjourn the Special Meeting if necessary to solicit additional proxies if there were not sufficient votes at the time of the Special Meeting to approve the Stock Issuance.

 

Item 8.01 Other Events.

On March 13, 2018, CVS Health issued a press release announcing the results of the stockholder vote on the Stock Issuance proposal at the Special Meeting. The full text of the press release, a copy of which is attached hereto as Exhibit 99.1, is incorporated herein by reference.

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction between CVS Health Corporation (“CVS Health”) and Aetna Inc. (“Aetna”), on February 9, 2018, CVS Health filed with the Securities and Exchange Commission (the “SEC”) an amendment to the registration statement on Form S-4 that was originally filed on January 4, 2018. The registration statement includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February 9, 2018, and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and shareholders of Aetna on or about February 12, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY


STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health are available free of charge within the Investors section of CVS Health’s Web site at http://www.cvshealth.com/investors or by contacting CVS Health’s Investor Relations Department at 800-201-0938. Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna’s internet website at http://www.Aetna.com or by contacting Aetna’s Investor Relations Department at 860-273-0896.

Cautionary Statement Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “explore,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “view,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health’s and Aetna’s control.

Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health’s and Aetna’s projections as to the closing date for the pending acquisition of Aetna (the “transaction”), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health’s and Aetna’s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health’s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health’s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health’s and Aetna’s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies’ pharmacy benefit business, the synergies from the transaction, and CVS Health’s, Aetna’s and/or the combined company’s future operating results, are based on CVS Health’s and Aetna’s managements’ estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the


proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health’s ability to promptly and effectively integrate Aetna’s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues.

In addition, this communication may contain forward-looking statements regarding CVS Health’s or Aetna’s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health’s or Aetna’s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health’s ability to complete the transaction and/or CVS Health’s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health’s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health’s and Aetna’s respective filings with the SEC, including the risk factors discussed in “Item 1.A. Risk Factors” in CVS Health’s and Aetna’s most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

You are cautioned not to place undue reliance on CVS Health’s and Aetna’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

 

Item 9.01. Financial Statements and Exhibits

(d) The following exhibits are included with this report:

 

Exhibit
No.
  

Description

99.1    Press Release, dated March 13, 2018, of CVS Health Corporation.


INDEX TO EXHIBITS

 

Exhibit
No.
  

Description

99.1    Press Release, dated March 13, 2018, of CVS Health Corporation.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CVS HEALTH CORPORATION

By:

 

/s/ Colleen M. McIntosh

  Colleen M. McIntosh
  Senior Vice President and Corporate Secretary
  Dated: March 13, 2018
EX-99.1 2 d507907dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

CVS Health Stockholders Approve Aetna Acquisition

Transaction expected to close in second half of 2018, subject to regulatory approvals

Combined company will focus on remaking the consumer health care experience,

lowering health care costs

WOONSOCKET, R.I., March 13, 2018 – In a special meeting held today, CVS Health Corporation (NYSE:CVS) stockholders voted to approve the shares of company stock to be issued in the company’s acquisition of Aetna Inc. (NYSE: AET), one of the nation’s leading diversified health care benefits companies. According to the preliminary results announced at the meeting, more than 98 percent of the shares voted were in favor of the proposal. The merger is expected to close in the second half of 2018, subject to required regulatory approvals.

“When this merger is complete, the combined company will be well-positioned to reshape the consumer health care experience, putting people at the center of health care delivery to ensure they have access to high-quality, more affordable care where they are, when they need it,” said Larry Merlo, CVS Health president and CEO.

The merger, once complete, will fill an unmet need in the U.S. health care system and presents a unique opportunity to redefine access to high-quality care in lower cost settings, whether in the community, in the home, or on the go through connected digital health care tools.

“The combination of CVS Health and Aetna brings together two complementary businesses with an expanded set of unique capabilities to create a new community-based open health care model that is easier to use and less expensive for consumers. We look forward to delivering more seamlessly coordinated care that ensures consumers have the essential resources to lead healthier lives for themselves and their families,” Merlo continued.

“At the same time, our company will benefit from a stronger market position, with the potential to deliver increased value through the development of innovative new products and services and generate long-term growth opportunities that help produce stronger, more consistent results for shareholders as a uniquely integrated health care company,” Merlo concluded.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,800 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty


pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Contacts:

Investors: Mike McGuire

Michael.McGuire@CVSHealth.com

401-770-4050

Media: Joseph Goode

Joseph.Goode@CVSHealth.com

401-770-9820

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction between CVS Health Corporation (“CVS Health”) and Aetna Inc. (“Aetna”), on February 9, 2018, CVS Health filed with the Securities and Exchange Commission (the “SEC”) an amendment to the registration statement on Form S-4 that was originally filed on January 4, 2018. The registration statement includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February 9, 2018, and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and shareholders of Aetna on or about February 12, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health are available free of charge within the Investors section of CVS Health’s Web site at http://www.cvshealth.com/investors or by contacting CVS Health’s Investor Relations Department at 800-201-0938. Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna’s internet website at http://www.Aetna.com or by contacting Aetna’s Investor Relations Department at 860-273-0896.

Participants in the Solicitation

CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 14, 2018, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March 31, 2017, and certain of its Current Reports on Form 8-K. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 23, 2018, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017, and certain of its Current Reports on Form 8-K. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive joint proxy statement/prospectus filed with the SEC and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “explore,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “outlook,” “plan,” “potential,”


“predict,” “probable,” “project,” “seek,” “should,” “view,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health’s and Aetna’s control.

Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health’s and Aetna’s projections as to the closing date for the pending acquisition of Aetna (the “transaction”), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health’s and Aetna’s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health’s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health’s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health’s and Aetna’s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies’ pharmacy benefit business, the synergies from the transaction, and CVS Health’s, Aetna’s and/or the combined company’s future operating results, are based on CVS Health’s and Aetna’s managements’ estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health’s ability to promptly and effectively integrate Aetna’s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues.

In addition, this communication may contain forward-looking statements regarding CVS Health’s or Aetna’s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health’s or Aetna’s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health’s ability to complete the transaction and/or CVS Health’s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health’s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health’s and Aetna’s respective filings with the SEC, including the risk factors discussed in “Item 1.A. Risk Factors” in CVS Health’s and Aetna’s most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

You are cautioned not to place undue reliance on CVS Health’s and Aetna’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

XXX

GRAPHIC 3 g507907g0313162800614.jpg GRAPHIC begin 644 g507907g0313162800614.jpg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g507907g0313163242669.jpg GRAPHIC begin 644 g507907g0313163242669.jpg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end